<DOC>
	<DOC>NCT00213473</DOC>
	<brief_summary>the aims of SACHA study was to appreciate prevalence, evolution and follow-up, treatment response of patients with acquired hemophilia with biological and clinical data. Inclusion criteria were factor VIIIc below 30% associated with presence of Facgteur VIII inhibitor (titer &gt; 1 u Bethesda. Clinical and biologival data were obtained at Day 0 (as soon as possible and at 1, 3, 6 and 12 months.Informations were notified to co-investigators with the help of two french medical society (Internal medicine, french haemostasis and thrombosis society.</brief_summary>
	<brief_title>Prospective Clinical and Biological Follow-up of Acquired Haemophilia : SACHA Study</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>Factor VIIIc &lt; 30% and Factor VIII inhibitor &gt; 1 u Bethesda absence and signed consent, haemophilia A</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>acquired haemophilia</keyword>
</DOC>